STOCKHOLM, March 27, 2018 /PRNewswire/ -- Cyxone announced today that the first phase of their cyclotide pilot study into inflammatory bowel disease (IBD) has been concluded as planned. The study was conducted after an inquiry by a pharmaceutical company that had observed Cyxone's...
from PR Newswire: //https://ift.tt/2pL3H0f
No comments:
Post a Comment